A review proposes targeting specific HSP90 proteins in ALS and other diseases
Original source
Isoform-selective HSP90 inhibition as a precision therapeutic strategy for neurodegenerative and metabolic diseases. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
A review describes isoform-selective inhibition of heat shock protein 90 (HSP90) as a possible treatment strategy for amyotrophic lateral sclerosis (ALS) and other diseases. It links abnormal HSP90 activity with toxic protein forms, impaired autophagy, mitochondrial dysfunction and ongoing inflammation in neurodegenerative disease. The authors say newer inhibitors are being designed to target individual HSP90 paralogs and enter the brain more effectively.
Why this matters
This may guide future laboratory research into treatments aimed at cellular protein-handling pathways in ALS. The source is a review of mechanisms and drug development, not evidence that these inhibitors improve ALS or are ready for patient treatment.
Limitations and context
This is a review article, not a clinical trial or a report of a new ALS treatment. The source does not provide results showing safety or benefit in people with ALS, nor does it establish that isoform-selective HSP90 inhibition works in ALS patients. Any proposed treatment would still need laboratory, animal and clinical testing.